Literature DB >> 30311380

Gene-specific criteria for PTEN variant curation: Recommendations from the ClinGen PTEN Expert Panel.

Jessica L Mester1, Rajarshi Ghosh2, Tina Pesaran3, Robert Huether4, Rachid Karam3, Kathleen S Hruska1, Helio A Costa5, Katherine Lachlan6,7, Joanne Ngeow8, Jill Barnholtz-Sloan9,10, Kaitlin Sesock11, Felicia Hernandez3, Liying Zhang12, Laura Milko13, Sharon E Plon2, Madhuri Hegde14,15, Charis Eng9,10,16.   

Abstract

The ClinGen PTEN Expert Panel was organized by the ClinGen Hereditary Cancer Clinical Domain Working Group to assemble clinicians, researchers, and molecular diagnosticians with PTEN expertise to develop specifications to the 2015 ACMG/AMP Sequence Variant Interpretation Guidelines for PTEN variant interpretation. We describe finalized PTEN-specific variant classification criteria and outcomes from pilot testing of 42 variants with benign/likely benign (BEN/LBEN), pathogenic/likely pathogenic (PATH/LPATH), uncertain significance (VUS), and conflicting (CONF) ClinVar assertions. Utilizing these rules, classifications concordant with ClinVar assertions were achieved for 14/15 (93.3%) BEN/LBEN and 16/16 (100%) PATH/LPATH ClinVar consensus variants for an overall concordance of 96.8% (30/31). The variant where agreement was not reached was a synonymous variant near a splice donor with noncanonical sequence for which in silico models cannot predict the native site. Applying these rules to six VUS and five CONF variants, adding shared internal laboratory data enabled one VUS to be classified as LBEN and two CONF variants to be as classified as PATH and LPATH. This study highlights the benefit of gene-specific criteria and the value of sharing internal laboratory data for variant interpretation. Our PTEN-specific criteria and expertly reviewed assertions should prove helpful for laboratories and others curating PTEN variants.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  ClinGen; PTEN; classification; criteria; variant

Mesh:

Substances:

Year:  2018        PMID: 30311380      PMCID: PMC6329583          DOI: 10.1002/humu.23636

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  54 in total

1.  Improved splice site detection in Genie.

Authors:  M G Reese; F H Eeckman; D Kulp; D Haussler
Journal:  J Comput Biol       Date:  1997       Impact factor: 1.479

2.  A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.

Authors:  Isabel Rodríguez-Escudero; María D Oliver; Amparo Andrés-Pons; María Molina; Víctor J Cid; Rafael Pulido
Journal:  Hum Mol Genet       Date:  2011-08-09       Impact factor: 6.150

3.  A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands.

Authors:  Min-Han Tan; Jessica Mester; Charissa Peterson; Yiran Yang; Jin-Lian Chen; Lisa A Rybicki; Kresimira Milas; Holly Pederson; Berna Remzi; Mohammed S Orloff; Charis Eng
Journal:  Am J Hum Genet       Date:  2010-12-30       Impact factor: 11.025

Review 4.  When overgrowth bumps into cancer: the PTEN-opathies.

Authors:  Jessica Mester; Charis Eng
Journal:  Am J Med Genet C Semin Med Genet       Date:  2013-05       Impact factor: 3.908

5.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

6.  Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers.

Authors:  K L Lachlan; A M Lucassen; D Bunyan; I K Temple
Journal:  J Med Genet       Date:  2007-05-25       Impact factor: 6.318

7.  Discovery and functional characterization of a neomorphic PTEN mutation.

Authors:  Helio A Costa; Michael G Leitner; Martin L Sos; Angeliki Mavrantoni; Anna Rychkova; Jeffrey R Johnson; Billy W Newton; Muh-Ching Yee; Francisco M De La Vega; James M Ford; Nevan J Krogan; Kevan M Shokat; Dominik Oliver; Christian R Halaszovich; Carlos D Bustamante
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-26       Impact factor: 11.205

8.  A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity.

Authors:  Anabel Gil; Isabel Rodríguez-Escudero; Miriam Stumpf; María Molina; Víctor J Cid; Rafael Pulido
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

9.  Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore.

Authors:  Edward S Y Wong; Sandhya Shekar; Marie Met-Domestici; Claire Chan; Melody Sze; Yoon Sim Yap; Steven G Rozen; Min-Han Tan; Peter Ang; Joanne Ngeow; Ann S G Lee
Journal:  NPJ Genom Med       Date:  2016-01-13       Impact factor: 8.617

10.  The ACMG/AMP reputable source criteria for the interpretation of sequence variants.

Authors:  Leslie G Biesecker; Steven M Harrison
Journal:  Genet Med       Date:  2018-12       Impact factor: 8.822

View more
  44 in total

1.  Variant Classification Concordance using the ACMG-AMP Variant Interpretation Guidelines across Nine Genomic Implementation Research Studies.

Authors:  Laura M Amendola; Kathleen Muenzen; Leslie G Biesecker; Kevin M Bowling; Greg M Cooper; Michael O Dorschner; Catherine Driscoll; Ann Katherine M Foreman; Katie Golden-Grant; John M Greally; Lucia Hindorff; Dona Kanavy; Vaidehi Jobanputra; Jennifer J Johnston; Eimear E Kenny; Shannon McNulty; Priyanka Murali; Jeffrey Ou; Bradford C Powell; Heidi L Rehm; Bradley Rolf; Tamara S Roman; Jessica Van Ziffle; Saurav Guha; Avinash Abhyankar; David Crosslin; Eric Venner; Bo Yuan; Hana Zouk; Gail P Jarvik
Journal:  Am J Hum Genet       Date:  2020-10-26       Impact factor: 11.025

2.  Overview of Specifications to the ACMG/AMP Variant Interpretation Guidelines.

Authors:  Steven M Harrison; Leslie G Biesecker; Heidi L Rehm
Journal:  Curr Protoc Hum Genet       Date:  2019-09

3.  ClinGen Variant Curation Expert Panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation.

Authors:  Edgar A Rivera-Muñoz; Laura V Milko; Steven M Harrison; Danielle R Azzariti; C Lisa Kurtz; Kristy Lee; Jessica L Mester; Meredith A Weaver; Erin Currey; William Craigen; Charis Eng; Birgit Funke; Madhuri Hegde; Ray E Hershberger; Rong Mao; Robert D Steiner; Lisa M Vincent; Christa L Martin; Sharon E Plon; Erin Ramos; Heidi L Rehm; Michael Watson; Jonathan S Berg
Journal:  Hum Mutat       Date:  2018-11       Impact factor: 4.878

Review 4.  PTEN-opathies: from biological insights to evidence-based precision medicine.

Authors:  Lamis Yehia; Joanne Ngeow; Charis Eng
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808

5.  Specifications of the variant curation guidelines for ITGA2B/ITGB3: ClinGen Platelet Disorder Variant Curation Panel.

Authors:  Justyne E Ross; Bing M Zhang; Kristy Lee; Shruthi Mohan; Brian R Branchford; Paul Bray; Stefanie N Dugan; Kathleen Freson; Paula G Heller; Walter H A Kahr; Michele P Lambert; Lori Luchtman-Jones; Minjie Luo; Juliana Perez Botero; Matthew T Rondina; Gabriella Ryan; Sarah Westbury; Wolfgang Bergmeier; Jorge Di Paola
Journal:  Blood Adv       Date:  2021-01-26

6.  Quantification of Discordant Variant Interpretations in a Large Family-Based Study of Li-Fraumeni Syndrome.

Authors:  Megan N Frone; Douglas R Stewart; Sharon A Savage; Payal P Khincha
Journal:  JCO Precis Oncol       Date:  2021-11-10

7.  Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants.

Authors:  Takae Brewer; Lamis Yehia; Peter Bazeley; Charis Eng
Journal:  Am J Hum Genet       Date:  2022-08-04       Impact factor: 11.043

8.  Clinical Interpretation of Sequence Variants.

Authors:  Junyu Zhang; Yanyi Yao; Haixian He; Jun Shen
Journal:  Curr Protoc Hum Genet       Date:  2020-06

9.  ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.

Authors:  Xi Luo; Simone Feurstein; Shruthi Mohan; Christopher C Porter; Sarah A Jackson; Sioban Keel; Michael Chicka; Anna L Brown; Chimene Kesserwan; Anupriya Agarwal; Minjie Luo; Zejuan Li; Justyne E Ross; Panagiotis Baliakas; Daniel Pineda-Alvarez; Courtney D DiNardo; Alison A Bertuch; Nikita Mehta; Tom Vulliamy; Ying Wang; Kim E Nichols; Luca Malcovati; Michael F Walsh; Lesley H Rawlings; Shannon K McWeeney; Jean Soulier; Anna Raimbault; Mark J Routbort; Liying Zhang; Gabriella Ryan; Nancy A Speck; Sharon E Plon; David Wu; Lucy A Godley
Journal:  Blood Adv       Date:  2019-10-22

10.  Specifications of the ACMG/AMP standards and guidelines for mitochondrial DNA variant interpretation.

Authors:  Elizabeth M McCormick; Marie T Lott; Matthew C Dulik; Lishuang Shen; Marcella Attimonelli; Ornella Vitale; Amel Karaa; Renkui Bai; Daniel E Pineda-Alvarez; Larry N Singh; Christine M Stanley; Stacey Wong; Anshu Bhardwaj; Daria Merkurjev; Rong Mao; Neal Sondheimer; Shiping Zhang; Vincent Procaccio; Douglas C Wallace; Xiaowu Gai; Marni J Falk
Journal:  Hum Mutat       Date:  2020-11-10       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.